

Belzutifan: A New dimension in management of ccRCC and VHL associated tumors



**Saturday,
17th October 2026**



**07:30 PM
onwards**



Dr. Eric Jonasch

**Professor, Genitourinary Medical Oncology, The University
of Texas MD Anderson Cancer Center, Houston, TX**

- A globally recognized authority in RCC, VHL Disease and HIF-2 α Biology
- Principal Investigator of the pivotal Belzutifan study in VHL disease-associated RCC and a leading researcher in Belzutifan clinical development.
- Vice Chair of the NCCN Kidney Cancer Panel, helping define Belzutifan's role in RCC and VHL treatment guidelines.

REGISTER NOW

Join the Discussion.

Save the Date

Managed by:

MICE IDEAS[®]
Meetings • Incentives • Conferences • Exhibitions
— Leader in Physical, Hybrid & Virtual Conferences —

15 years of
Excellence

Rajesh Sharma
M: 9374073512
E: rajesh@miceideas.in

Belzutifan: A New Dimension in the Management of ccRCC & VHL Associated Tumors



17th October 2026,
Saturday



7:30pm Onwards



Session Leads

Programme Director

Dr. A. K. Vaid

Delhi

Opening Remarks &
Context Setting

International Speaker

Dr. Eric Jonasch

MD Anderson Cancer Center, USA

Expert Lecture

Moderator

Dr. Senthil J. Rajappa

Hyderabad

Expert Panel Discussion

Expert Advisors



Dr. Amit Joshi

Actrec- Tata Memorial Centre
Navi Mumbai



Dr. Deepak Dabkara

Tata Medical Center,
Kolkata



Dr. Eric Jonasch

The University of Texas MD
Anderson Cancer Center,
Houston, TX



Dr. Joydeep Ghosh

Apollo Multispeciality Hospital,
Kolkata



Dr. Kaushal Patel

Elite Hemat Onco Care
Centre, Surat



Dr. MVT Krishna Mohan

Basavatarakam Indo American
Cancer Hospital & Research
Institute, Hyderabad



Dr. Sachin Gupta

Max Hospital, Mohali



Dr. Sai Vivek

Aster Hospital, Bangalore



Dr. Sandeep Batra

Max Smart Super Speciality
Hospital, Saket (New Delhi)



Dr. Vineet Govinda Gupta

Fortis Shalimar Bagh

Belzutifan: A New Dimension in the Management of ccRCC & VHL Associated Tumors

Timing (IST)	Session Topic	Faculty / Speaker
07:30pm - 07:35pm	Welcome Address	Host
07:35pm - 07:45pm	Opening & Context setting- Current Landscape & unmet needs in the management of ccRCC & VHL associated Tumors in India	Dr A. K. Vaid, Programme Director
07:45pm - 08:25pm	ISP Expert Lecture Belzutifan: A First in class HIF 2 α inhibitor in the management of ccRCC & VHL associated Tumors	Dr. Eric Jonasch, ISP
08:25pm - 09:10pm	Expert Panel Discussion From Evidence to Practice: Integrating Belzutifan into clinical practice -Where, When & for whom	Dr. Senthil J. Rajappa, Moderator
09:10pm - 09:15pm	Vote of Thanks & Closing Remarks	Dr A. K. Vaid, Programme Director

Join the Discussion.

REGISTER NOW



Save the Date